Evidence map›Paper›PMID 35397683›Full record

ArticleMolecular and cellular biochemistry2022

Monoclonal antibody Daratumumab promotes macrophage-mediated anti-myeloma phagocytic activity via engaging FC gamma receptor and activation of macrophages.

Ying Gao, Lan Li, Yan Zheng, Weihua Zhang, Ben Niu, Yu Li

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Harnessing chimeric antigen receptor macrophages against solid tumors.Cancer communications (London, England) · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ying Gao *Department of Infectious Diseases, Shaanxi Provincial People's Hospital, The Affiliated Hospital of Xi'an Medical University, 256 West Youyi Road, Xi'an, 710068, China.
Lan Li *Department of Infectious Diseases, Shaanxi Provincial People's Hospital, The Affiliated Hospital of Xi'an Medical University, 256 West Youyi Road, Xi'an, 710068, China.
Yan ZhengDepartment of Infectious Diseases, Shaanxi Provincial People's Hospital, The Affiliated Hospital of Xi'an Medical University, 256 West Youyi Road, Xi'an, 710068, China.
Weihua ZhangDepartment of Infectious Diseases, Shaanxi Provincial People's Hospital, The Affiliated Hospital of Xi'an Medical University, 256 West Youyi Road, Xi'an, 710068, China.
Ben NiuDepartment of Infectious Diseases, Shaanxi Provincial People's Hospital, The Affiliated Hospital of Xi'an Medical University, 256 West Youyi Road, Xi'an, 710068, China.
Yu LiDepartment of Infectious Diseases, Shaanxi Provincial People's Hospital, The Affiliated Hospital of Xi'an Medical University, 256 West Youyi Road, Xi'an, 710068, China. yuli19811@outlook.com.ORCID http://orcid.org/0000-0002-1003-3354
Shanxi Medical University · CN

Funding

Xian Foundation for Development of Science and Technology, China 20YXYJ0009(11)
6 · The paper itself

Abstract

Daratumumab (DAR) is novel human anti-CD38 IgG1, high-affinity human monoclonal antibody having broad-spectrum killing activity. The antibody is recommended to treat multiple myeloma. Recently Antibody-dependent cellular phagocytosis (ADCP) have been identified as the potential mechanism of DAR in addition to complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). In the present study we evaluated the effect of Daratumumab on other effector cells of multiple myeloma. Luciferase

Indexed as

Antibodies, MonoclonalMacrophagesMultiple MyelomaReceptors, IgGAnimalsHumansMiceMice, SCIDAntibodies, MonoclonaldaratumumabReceptors, IgGAnti-tumourDaratumumabFc-FcγRMultiple myeloma

Identifiers

PMID35397683
OpenAlexW4223552008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.